{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Anti-Glomerular Basement Membrane Disease', 'Alemtuzumab has also been associated with anti-GBM disease, which can cause a', \"pulmonaryrenal syndrome known as Goodpasture's disease. (Clatworthy, 2008, N Engl J Med;\", 'Coles, 2006, J Neurol) Anti-GBM disease is a rare autoimmune disorder in which circulating', 'antibodies are directed against an antigen normally present in the basement membranes of renal', 'glomeruli and pulmonary alveoli. The target antigen is the alpha-3 chain of type IV collagen. The', 'resultant clinical syndrome encompasses a spectrum ranging from mild or no renal involvement to', 'rapidly progressive glomerulonephritis. Patients may develop pulmonary hemorrhage. Signs and', 'symptoms that commonly occur in patients with antiGBM disease include:', 'Gross hematuria (red or tea colored urine).', 'Hemoptysis.', 'Edema (particularly lower extremity edema).', 'Nonspecific symptoms can include malaise, fatigue, upper respiratory infection, rash.', 'In an effort to identify potential cases of antiGBM disease early, all patients will undergo monthly', 'evaluation of serum creatinine levels alone or as part of a full chemistry panel and laboratory', 'urinalysis (minimally including examination of protein and hemoglobin) with microscopy. Follow', 'up of abnormal results will be guided by the algorithm below in 2 the figures below.', 'Monthly Urinalysis and Serum Creatinine', 'Monthly Urinalysis with Microscopy*, SCr', '(Performed at Central Lab; local lab permissible but not preferred)', 'Negative for', 'Negative for Blood', 'Positive for', 'Blood', 'Positive for Protein and/or', 'Blood', 'WBC', 'Normal SCr', 'Abnormal SCr', 'Normal SCr', 'Abnormal SCr', 'See Fig. 9-2', '(or, if baseline SCr is', '(or, if baseline SCr is', 'abnormal, increase of', 'abnormal, increase of', '25%)', '25%)', 'Continue', 'Site evaluation,', 'Site evaluation,', 'Monitoring', 'Referral to nephrologist for', 'Non-urgent referral to', 'Treat UTI if indicated,', 'non-GBM disease', 'nephrologist', 'Non-urgent referral to', 'nephrologist', 'Abbreviations: SCr=Serum creatinine; GBM=glomerular basement membrane; UTI=urinary tract infection; WBC=white blood cells', '*Morning urine preferred; false positive rate high during menses and one week after. If monthly urinalysis is positive for blood, SCr is', 'normal, and the patient is menstruating, the urinalysis should be repeated one week following menses. If a patient has chronic', 'microscopic hematuria or proteinuria that is being evaluated or already adequately evaluated, monthly surveillance should focus on', 'changes in these levels and on SCr.', 'Property of the Sanofi Group - strictly confidential', 'Page 107', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Follow-up of Abnormal Urine or Serum Creatinine Results', 'Monthly Urinalysis with Microscopy, SCr', 'V', 'Positive for Blood', 'Normal SCr but increase from baseline* or', 'Normal SCr and no increase from baseline*', 'Abnormal SCr', 'screening', 'or screening', '>50% increase', '<50% increase', 'HIGH concern, URGENT referral', 'Repeat Urinalysis with', 'WEEKLY Urinalysis with Microscopy &', 'to nephrologist**', 'Microscopy', '& SCr in 2-3 days', 'SCr for up to 3 weeks', 'YES', 'SCr', 'Repeat normal or stable', 'If at any time blood', 'Persistent microscopic', 'increasing?', 'clears and SCr is', 'hematuria with normal', 'normal or unchanged', 'SCr X 3 weeks', 'Blood', 'No blood', 'persists', 'Site evaluation, non-', 'Resume routine', 'Resume routine', 'Non-urgent referral to a', 'urgent referral to', 'monitoring', 'monitoring', 'nephrologist', 'nephrologist', 'Abbreviations: SCr=serum creatinine', '*Comparison is versus the lowest of pre-treatment values for that patient.', '**While awaiting nephrology consult, consider repeating SCr in 2-3 days and refer emergently/consider hospitalization if', 'SCr rising.', 'Property of the Sanofi Group - strictly confidential', 'VV-CLIN-02544065', 'Page 108']\n\n###\n\n", "completion": "END"}